Targeting Brain Metastases in Patients with Melanoma

Table 1

Cinical trials of targeted or immune modulatory drugs in patients with melanoma metastatic to the brain with report PFS or OS.

Trial	Type	Number of patients (𝑛)	Treatment	RR in brain 𝑛 (%)	PFS (months)	OS (months)	Intracranial bleeding (Y/N)
Falchook et al. [13]	1-2	10	Dabrafenib	9/10 (90%)	4.2	NR	NR
Long et al. [14]	2	172; (i) 89 untreated; (ii) 83 pretreated	Dabrafenib	Untreated; Val600Glu: 29/74 (39.2%); Val600Lys: 1/15 (6.7%); Pretreated; Val600Glu: 20/65 (30.8%); Val600Lys: 4/18 (22.2%)	Untreated; Val600Glu: 16.1; Val600Lys: 8.1; Pretreated; Val600Glu: 16.6; Val600Lys: 15.9	Untreated; Val600Glu: 33.1; Val600Lys: 16.3; Pretreated; Val600Glu: 31.4; Val600Lys: 21.9	1/172
Chu et al. [20]	Retro-; spective; review	8	High dose IL-2	1/8 (12.5%)	NR	6.7	NR
Margolin et al. [24]	2	72; (i) 51 asymptomatic; (ii) 21 symptomatic	Ipilimumab	Asymptomatic: 8/51 (16); Symptomatic: 1/21 (5%)	Asymptomatic: 1.5; Symptomatic: 1.2	Asymptomatic: 7 Symptomatic: 3.7	0
Hong et al. [25]	Retro-; spective; review	26	Adoptive cell therapy	ACT-TIL: 7/17 (41%); TCR-transduced lymphocytes: 2/9 (22%)	NR	ACT-TIL: 8.5; TCR-transduced lymphocutes: 15	1/26
Amaravadi et al. [26]	2	53	Temozolomide; and sorafenib	NR	3.5	8	0
Di Giacomo et al. [28]	2	20	Ipilimumab and fotemustine	11/20 (55%) disease control	4.5	13.4	NR
Knisely et al. [30]	Retro-spective; review	77	Ipilimumab after radiosurgery	NR	NR	21.3	NR
Narayana et al. [32]	Retro-spective; review	12	Vemurafenib	36/48 (75%)	NR	NR	4/12
Total		450

RR: response rate, PFS: progression free survival, OS: overall survival, NR: nonreported, ACT: adoptive cell therapy, TIL: tumor-infiltrating lymphocytes, TCR: T-cell receptor.